Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

Juliana B. Candido

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-7462-9527; OpenAlex author ID A5108959203. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells. First author DOI 10.1016/j.actbio.2025.12.020↗
  2. CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells. Co-author DOI 10.1126/sciadv.adi0244↗
  3. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  4. Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13163969↗
  5. 3D approaches to model the tumor microenvironment of pancreatic cancer. Co-author DOI 10.7150/thno.42441↗
  6. Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Ce… First author DOI 10.3389/fimmu.2019.00542↗
  7. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  8. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. Co-author DOI 10.1172/jci45797↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniela Loessner · 3 shared papers, 2020–2026 · strength 0.55
  2. Elena Tomás Bort · 3 shared papers, 2020–2026 · strength 0.55
  3. Hemant Mahendrakumar Kocher · 3 shared papers, 2019–2026 · strength 0.52
  4. Shreya Sharma · 2 shared papers, 2020–2026 · strength 0.43
  5. Eleni Maniati · 3 shared papers, 2011–2026 · strength 0.41
  6. Eleonora Peerani · 2 shared papers, 2021–2026 · strength 0.41
  7. Rodrigo Curvello · 1 shared paper, 2026 · strength 0.29
  8. Jun Wang · 1 shared paper, 2026 · strength 0.29
  9. Victoria Sanz‐Moreno · 2 shared papers, 2021–2023 · strength 0.25
  10. Markus Kieler · 1 shared paper, 2020 · strength 0.15
  11. Rémi Samain · 1 shared paper, 2023 · strength 0.13
  12. Claire M. Wells · 1 shared paper, 2023 · strength 0.13
  13. Debashis Sarker · 1 shared paper, 2023 · strength 0.13
  14. Wilko Weichert · 1 shared paper, 2021 · strength 0.12
  15. Verena Kast · 1 shared paper, 2021 · strength 0.12
  16. Melania Capasso · 1 shared paper, 2019 · strength 0.10
  17. Sarah Spear · 1 shared paper, 2019 · strength 0.10
  18. Thomas R. Jeffry Evans · 1 shared paper, 2016 · strength 0.04
  19. Mona Foth · 1 shared paper, 2016 · strength 0.04
  20. Colin William Steele · 1 shared paper, 2016 · strength 0.04
  21. Peter J. Bailey · 1 shared paper, 2016 · strength 0.04
  22. Simon T. Barry · 1 shared paper, 2016 · strength 0.04
  23. Nigel Balfour Jamieson · 1 shared paper, 2016 · strength 0.04
  24. C. Ross Carter · 1 shared paper, 2016 · strength 0.04
  25. Jennifer P. Morton · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.